Author

J. F. Sarthy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Assay:ChIP-seq· 2 Research Focus:chromatin & epigenetic regulation· 2 Assay:scRNA-seq· 2

Frequent Co-Authors

S. Henikoff· 3 shared D. H. Janssens· 2 shared K. Ahmad· 2 shared M. P. Meers· 2 shared S. Meshinchi· 2 shared A. A. Apfelbaum· 1 shared A. Bose· 1 shared A. D. Choudhury· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

S. Henikoff

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

KMT2A oncoproteins induce epigenetic resistance to targeted therapies

D. H. Janssens, M. Duran, D. J. Otto, W. Wu, Y. Xu, D. Kirkey, C. G. Mullighan, J. S. Yi, S. Meshinchi, J. F. Sarthy, K. Ahmad, S. Henikoff

This study shows KMT2A oncoproteins drive lineage-switching and epigenetic resistance in leukemia by dynamically binding chromatin and persisting as ENL-marked lesions despite therapy.

bioRxiv · Dec 29, 2023 · PreprintCancer Biology

Chromatin Profiling of CBFA2T3-GLIS2 AMLs Identifies Key Transcription Factor Dependencies and BRG1 Inhibition as a Novel Therapeutic Strategy

S. Kaonis, J. L. Smith, N. Katiyar, M. Merrill, T. Hylkema, S. Namciu, Q. Le, E. Babaeva, T. Ikeda, S. M. Morris, E. Girard, S. Furuyama, R. Ries, I. Bernstein, S. Meshinchi, , J. F. Sarthy

This study identifies BRG1 inhibition as a therapeutic strategy for CBFA2T3-GLIS2 AML by analyzing chromatin profiles and CRISPR dependencies.

bioRxiv · Aug 30, 2023 · PreprintCancer Biology

Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes

N. De Sarkar, R. D. Patton, A.-L. Doebley, B. Hanratty, A. J. Kreitzman, J. F. Sarthy, M. Ko, M. Adil, S. Brahma, M. P. Meers, D. H. Janssens, L. S. Ang, I. Coleman, A. Bose, R. F. Dumpit, , G. Ha

This paper identifies nucleosome patterns in ctDNA that distinguish advanced prostate cancer phenotypes, achieving high accuracy in classification using a prediction model.

bioRxiv · Jun 21, 2022Cancer Biology

HOXD13 is a direct EWS-FLI1 target and moderates fusion-dependent transcriptional states

A. A. Apfelbaum, F. Wu, A. Hawkins, J. A. Jimenez, S. D. Taylor, E. R. Pfaltzgraff, J. Y. Song, C. Hall, D. M. Wellik, M. Ljungman, S. N. Furlan, R. J. H. Ryan, J. F. Sarthy, E. R. Lawlor

The paper identifies HOXD13 as a direct target of EWS-FLI1 and shows it modulates transcriptional states in Ewing sarcoma by antagonizing EWS-FLI1-dependent gene repression.

bioRxiv · Jan 31, 2022 · PreprintCancer Biology